Vismodegib for advanced basal cell carcinoma: Duration of response after vismodegib discontinuation and response to vismodegib retreatment upon disease progression

9081 Background: Vismodegib (VISMO) (Erivedge) is a first-in-class Hedgehog pathway inhibitor (HPI) approved for advanced basal cell carcinoma (aBCC). In the ERIVANCE trial, VISMO-treated patients (pts) demonstrated objective response rates (ORRs) by independent review of 30% in metastatic BCC (mBCC; n=33) and 43% in locally advanced BCC (laBCC; n=63). ORRs by investigator (INV) review were 45% (mBCC) and 60% (laBCC). Treatment on VISMO may be prolonged, and a number of pts discontinued treatment prior to progression on therapy. Here we provide results from a survey designed to assess durability of response in laBCC pts from ERIVANCE who discontinued VISMO while experiencing a response or stable disease (SD). We also determined whether they responded to retreatment with VISMO. Methods: As of May 28, 2012, we identified 13 pts who did not have progressive disease (PD) at the time of study discontinuation and were still alive and available for follow-up.In Oct 2012, a survey was sent to INVs to determine pt...